AdaptHealth Corp. (AHCO)
$7.20
-0.05 (-0.69%)Delayed quote.
Price history
Daily close- Start
- $9.86
- Latest close
- $7.20
- Period change
- -26.98%
- Period low
- $5.22
- Period high
- $13.38
Key metrics
- Market cap
- $982.98M
- Volume
- 1.07M
- Average volume
- 2.84M
- 52-week range
- $5.21 – $13.43
- Beta
- 1.32
- Last dividend
- —
- EPS (TTM)
- -$2.98
- P/E ratio
- -19.15
- Revenue (TTM)
- $3.15B
- Net income (TTM)
- -$406.73M
- Total assets
- $4.20B
- Total debt
- $2.05B
- Cash and equivalents
- $80.69M
Key financials (trailing twelve months).
Company profile
AdaptHealth Corp., alongside its network of subsidiaries, delivers a comprehensive range of home medical equipment (HME), supplies, and associated services across the United States. The company specializes in sleep therapy, providing CPAP and bi-PAP devices and support for individuals managing obstructive sleep apnea. It also furnishes essential medical devices and provisions for diabetes treatment, such as continuous glucose monitors and insulin pumps. AdaptHealth supplies HME to patients transitioning from acute care settings, offers in-home oxygen and chronic therapy services, and caters to chronically ill patients with specialized equipment and supplies for wound care, urological, incontinence, ostomy, and nutritional needs. These services are accessible to beneficiaries of Medicare, Medicaid, and various commercial insurance payors. AdaptHealth Corp. is primarily based in Plymouth Meeting, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NASDAQ
- CEO
- Suzanne Foster
- Employees
- 10,900
- Headquarters
- Conshohocken, PA, US
- IPO date
- 2018-05-31
- Website
- https://adapthealth.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $3.24B | $3.26B | $3.20B |
| Gross profit | $568.56M | $681.09M | $681.77M |
| Operating income | $186.27M | $263.73M | -$598.40M |
| EBITDA | $472.53M | $628.02M | -$171.09M |
| Net income | -$70.79M | $90.42M | -$678.89M |
| Diluted EPS | -$0.52 | $0.61 | -$5.31 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $106.14M | $109.75M | $77.13M |
| Total assets | $4.32B | $4.49B | $4.51B |
| Total liabilities | $2.79B | $2.91B | $3.04B |
| Total debt | $1.90B | $2.13B | $2.29B |
| Shareholders’ equity | $1.52B | $1.57B | $1.46B |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | $601.77M | $541.84M | $480.67M |
| Capital expenditure | -$382.39M | -$306.06M | -$337.46M |
| Free cash flow | $219.38M | $235.78M | $143.20M |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Apr 10, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $745.65M | $740.31M | $819.80M | $846.29M | $602.63M | $591.81M |
| Gross profit | $114.81M | $104.21M | $101.40M | $162.23M | -$55.74M | -$53.90M |
| Operating income | -$155.92M | -$137.80M | $6.89M | $54.34M | $67.13M | $79.25M |
| EBITDA | -$39.02M | -$16.18M | $111.96M | $23.95M | $170.94M | $156.78M |
| Net income | -$153.99M | -$133.93M | -$16.04M | -$102.77M | $24.51M | $14.67M |
| Diluted EPS | -$1.13 | -$0.99 | -$0.12 | -$0.73 | $0.16 | $0.10 |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Apr 10, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $80.69M | $43.29M | $47.96M | $106.14M | $80.36M | $68.63M |
| Total assets | $4.20B | $4.34B | $4.42B | $4.32B | $4.38B | $4.35B |
| Total liabilities | $2.97B | $2.95B | $2.91B | $2.79B | $2.76B | $2.76B |
| Total debt | $2.05B | $2.07B | $2.00B | $1.90B | $1.90B | $1.95B |
| Shareholders’ equity | $1.23B | $1.38B | $1.51B | $1.52B | $1.62B | $1.59B |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Apr 10, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $156.59M | $145.30M | $93.72M | $183.18M | $161.07M | $161.99M |
| Capital expenditure | -$105.53M | -$166.24M | -$121.21M | -$103.90M | -$94.24M | -$88.67M |
| Free cash flow | $51.06M | -$20.94M | -$27.49M | $79.29M | $66.82M | $73.33M |